Table 4.
Overlapping KEGG pathways between potential drugs and breast cancer
| Drug Name | Overlapping enriched pathways | p-value |
|---|---|---|
| Nadroparin | hsa05210: Colorectal cancer hsa05161: Hepatitis B hsa05166: HTLV-I infection hsa05200: Pathways in cancer |
0.00897 0.02098 0.03704 0.04687 |
| Regorafenib | hsa04015: Rap1 signaling pathway | 3.41E-14 |
| hsa04014: Ras signaling pathway | 7.18E-14 | |
| hsa04151: PI3K-Akt signaling pathway | 3.36E-10 | |
| hsa05230: Central carbon metabolism in cancer | 4.38E-08 | |
| hsa05215: Prostate cancer | 2.21E-07 | |
| hsa05200: Pathways in cancer | 1.13E-06 | |
| hsa05218: Melanoma | 4.76E-06 | |
| hsa05214: Glioma | 1.65E-04 | |
| hsa05221: Acute myeloid leukemia | 0.00404 | |
| hsa05205: Proteoglycans in cancer | 0.00433 | |
| hsa05220: Chronic myeloid leukemia | 0.00660 | |
| hsa04012: ErbB signaling pathway | 0.00952 | |
| hsa05206: MicroRNAs in cancer | 0.01157 | |
| hsa05231: Choline metabolism in cancer | 0.01269 | |
| hsa04722: Neurotrophin signaling pathway | 0.01761 |